Diabetes Division, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA.
Diabetologia. 2011 Dec;54(12):3132-42. doi: 10.1007/s00125-011-2289-z. Epub 2011 Sep 7.
AIMS/HYPOTHESIS: The mechanisms by which transcription factor 7-like 2 (TCF7L2) regulates the pathways that are important in the pathogenesis of type 2 diabetes are unknown. We therefore examined the role of TCF7L2 in hepatic glucose production (HGP) in vitro and characterised the whole-genome chromatin occupancy of TCF7L2 in hepatocytes.
We investigated the effect of TCF7L2 silencing and overexpression on HGP from gluconeogenic precursors and used chromatin-immunoprecipitation (ChIP) combined with massively parallel DNA sequencing (ChIP-Seq) to investigate the DNA binding patterns of TCF7L2 across the whole genome.
Silencing of TCF7L2 induced a marked increase in basal HGP, which was accompanied by significant increases in the expression of the gluconeogenic genes Fbp1, Pck1 and G6pc. Overexpression of Tcf7l2 reversed this phenotype and significantly reduced HGP. TCF7L2 silencing did not affect the half-maximal inhibitory concentration of insulin or metformin, but HGP remained elevated in TCF7L2-silenced cells due to the increased baseline HGP. Using ChIP-Seq, we detected 2,119 binding events across the genome. Pathway analysis demonstrated that diabetes genes were significantly over-represented in the dataset. Our results indicate that TCF7L2 binds directly to multiple genes that are important in regulation of glucose metabolism in the liver, including Pck1, Fbp1, Irs1, Irs2, Akt2, Adipor1, Pdk4 and Cpt1a.
CONCLUSIONS/INTERPRETATION: TCF7L2 is an important regulator of HGP in vitro and binds directly to genes that are important in pathways of glucose metabolism in the liver. These data highlight the possibility that TCF7L2 may affect fasting and postprandial hyperglycaemia in carriers of at-risk TCF7L2 genetic polymorphisms.
目的/假设:转录因子 7 样 2(TCF7L2)调节 2 型糖尿病发病机制中重要途径的机制尚不清楚。因此,我们研究了 TCF7L2 在体外肝葡萄糖生成(HGP)中的作用,并对肝细胞中 TCF7L2 的全基因组染色质占据进行了特征描述。
我们研究了 TCF7L2 沉默和过表达对来自糖异生前体的 HGP 的影响,并使用染色质免疫沉淀(ChIP)与大规模平行 DNA 测序(ChIP-Seq)相结合,研究 TCF7L2 在整个基因组上的 DNA 结合模式。
TCF7L2 的沉默诱导了基础 HGP 的显著增加,伴随着糖异生基因 Fbp1、Pck1 和 G6pc 的表达显著增加。Tcf7l2 的过表达逆转了这种表型,并显著降低了 HGP。TCF7L2 的沉默不影响胰岛素或二甲双胍的半最大抑制浓度,但由于基础 HGP 的增加,TCF7L2 沉默细胞中的 HGP 仍然升高。使用 ChIP-Seq,我们在整个基因组中检测到 2119 个结合事件。途径分析表明,糖尿病基因在数据集内显著过表达。我们的结果表明,TCF7L2 直接结合多个在肝脏葡萄糖代谢调节中重要的基因,包括 Pck1、Fbp1、Irs1、Irs2、Akt2、Adipor1、Pdk4 和 Cpt1a。
结论/解释:TCF7L2 是体外 HGP 的重要调节因子,直接结合在肝脏葡萄糖代谢途径中重要的基因上。这些数据突出表明,TCF7L2 可能会影响携带风险 TCF7L2 遗传多态性的个体的空腹和餐后高血糖。